Article
Biochemistry & Molecular Biology
Vittoria Cammisotto, Francesco Baratta, Paola G. Simeone, Cristina Barale, Enrico Lupia, Gioacchino Galardo, Francesca Santilli, Isabella Russo, Pasquale Pignatelli
Summary: PCSK9 is involved in cholesterol metabolism and plays a role in the development of atherosclerosis and atherothrombotic processes, promoting plaque formation and oxidative stress.
Article
Biotechnology & Applied Microbiology
Zhenxian Li, Haimei Zhu, Hao Liu, Dayue Liu, Jianhe Liu, Jiazheng Jiang, Yi Zhang, Zhang Qin, Yijia Xu, Yuan Peng, Bin Liu, Yun Long
Summary: In this study, a biomimetic nanoliposome loaded with Evolocumab (a PCSK9 inhibitor) was developed using nano-materials to alleviate atherosclerosis. The results showed that this nanoliposome can inhibit the phenotypic transition, excessive proliferation, and migration of VSMCs. Additionally, it significantly decreased the expression of PCSK9 in serum and VSMCs within the plaque of ApoE(-/-) mice.
JOURNAL OF NANOBIOTECHNOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Coen van Solingen, Scott R. Oldebeken, Alessandro G. Salerno, Amarylis C. B. A. Wanschel, Kathryn J. Moore
Summary: The discovery of PCSK9 and its role in LDL regulation has led to the rapid development of therapeutic PCSK9 inhibitors. Research has identified certain microRNAs that can reduce PCSK9 expression, leading to increased LDLR expression in hepatic cells, which may have therapeutic implications for manipulating LDLR expression and cholesterol levels in the liver.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Medical Laboratory Technology
Antonin Jabor, Tereza Vackova, Zdenek Kubicek, Jitka Komrskova, Marek Protus, Janka Franekova
Summary: The study evaluated the biological variation of serum PCSK9, finding a high within-subject variability in healthy individuals, suggesting that common reference intervals can be used to interpret its values.
CLINICA CHIMICA ACTA
(2021)
Article
Medical Laboratory Technology
Jia-ni Xu, Ting-ting Wang, Hong Shu, Shun-yi Shi, Li-chan Tao, Jian-Jun Li
Summary: Diabetes mellitus (DM) is strongly associated with atherosclerotic cardiovascular disease (ASCVD), and the protein PCSK9 has been identified as a key regulator of LDL-C levels and a potential target for improving cardiovascular outcomes. Recent studies have also linked PCSK9 to glucose metabolism, and clinical trials suggest that PCSK9 inhibitors are more effective in treating patients with DM. This review summarizes the current findings on the association between PCSK9 and glucose metabolism, including the effects of PCSK9 genetic mutations, plasma PCSK9 concentrations, and glucose-lowering drugs on metabolic parameters, as well as the impact of PCSK9 inhibitors on cardiovascular outcomes in patients with DM.
CLINICA CHIMICA ACTA
(2023)
Article
Medicine, General & Internal
Jonathan Grimm, Georg Peschel, Martina Mueller, Doris Schacherer, Reiner Wiest, Kilian Weigand, Christa Buechler
Summary: This study found that serum PCSK9 levels were associated with liver injury and inflammation in cirrhotic HCV patients, but not with LDL levels. After DAA therapy, PCSK9 decreased and LDL increased in non-cirrhotic HCV patients, while no changes were observed in the cirrhotic group.
JOURNAL OF CLINICAL MEDICINE
(2021)
Editorial Material
Cardiac & Cardiovascular Systems
Jia Peng, Cheng-Gang Zhu, Jian-Jun Li
Summary: Increasing data suggest that PCSK9 may play a role in the development of type 2 diabetes and be associated with clinical outcomes in diabetic patients, but there is currently no general agreement about the association of PCSK9 with T2DM. The utility of circulating PCSK9 concentration as a predictor for the risk of new-onset T2DM should be considered clinically prudent.
CARDIOVASCULAR DIABETOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Ioannis Farmakis, Ioannis Doundoulakis, Areti Pagiantza, Stefanos Zafeiropoulos, Christina Antza, Haralambos Karvounis, George Giannakoulas
Summary: PCSK9 inhibitors have been shown to lower Lipoprotein(a) levels, with significant heterogeneity in their effects. Differences in comparator and treatment duration can influence the impact of PCSK9 inhibitors on Lipoprotein(a) levels.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Fang Jia, Si-Fan Fei, De-Bing Tong, Cong Xue, Jian-Jun Li
Summary: PCSK9 increases circulating LDL-C levels by degrading LDL receptors and has direct effects on atherosclerosis and coronary plaque inflammation. Emerging data show higher PCSK9 concentrations in women than men, suggesting potential sex differences in PCSK9 roles and clinical implications.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Miao Yu, Wenjing Tang, Wei Liang, Baikang Xie, Ran Gao, Peiwu Ding, Xiaoying Gu, Min Wang, Shuang Wen, Peng Sun
Summary: Proprotein convertase subtilisin kexin type 9 (PCSK9) was initially known for its role in regulating cholesterol metabolism, but recent studies have shown its involvement in inflammatory and autoimmune diseases unrelated to cholesterol alterations. This study aims to investigate the roles and mechanisms of PCSK9 in myocarditis and found that PCSK9 inhibition can ameliorate the severity of myocarditis by reducing Th17 cell differentiation. PCSK9 appears to be a promising target for treating myocarditis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Cell Biology
Liuxin Ning, Yanting Zou, Shuyu Li, Yue Cao, Beili Xu, Shuncai Zhang, Yu Cai
Summary: The study aimed to investigate the mechanism of anti-PCSK9 treatment on liver fibrosis by inhibiting hypoxia-induced autophagy. The results showed that anti-PCSK9 treatment could alleviate liver inflammation and fibrosis by regulating the AMPK/mTOR/ULK1 signaling pathway to reduce hypoxia-induced autophagy in hepatocytes.
Review
Integrative & Complementary Medicine
Su-su Liu, Tong Yu, Yan-fang Qiao, Shu-xiao Gu, Xin-lou Chai
Summary: The prevalence of hyperlipidemia has increased significantly due to various factors and has become a common pathological condition. High circulating LDL-C is one of the causes of hyperlipidemia. LDL-C regulates cholesterol homeostasis through binding to LDLR, while PCSK9 mediates LDLR degradation, leading to hyperlipidemia. Targeting PCSK9-synthesizing transcription factors and downstream molecules is important for developing new lipid-lowering drugs.
CHINESE JOURNAL OF INTEGRATIVE MEDICINE
(2023)
Article
Endocrinology & Metabolism
Yiming Wu, Jie Shi, Qing Su, Zhen Yang, Li Qin
Summary: This study found that circulating PCSK9 levels were significantly higher in pregnant women with gestational diabetes mellitus (GDM) compared to those with normal glucose tolerance. The levels of PCSK9 were positively correlated with fasting plasma glucose, glycated hemoglobin, total cholesterol, and low-density lipoprotein cholesterol in the GDM group. Logistic regression analysis showed that age and serum PCSK9 levels were independently associated with GDM. The study suggests a potential link between PCSK9 and GDM.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Giuseppe Derosa, Pamela Maffioli, Angela D'Angelo, Andrea Girola, Emanuela Colombo, Anna Maria Fiorenza, Jose J. Ceballos Macias, Carolina L. Sanchez, Riccardo Raddino, Gian Franco Pasini, Marco Triggiani, Andrea M. Maresca, Nicolo Tandurella, Luigina Guasti
Summary: This study demonstrates that PCSK9 inhibitors are well tolerated and provide long-term significant lowering of LDL-C in individuals with hyperlipidemia.
JOURNAL OF CARDIOVASCULAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Zhicai Feng, Xiangyu Liao, Juan Peng, Jingjing Quan, Hao Zhang, Zhijun Huang, Bin Yi
Summary: Our research demonstrates that PCSK9 contributes to aggravated inflammation in the kidneys through triggering mitochondrial DNA damage and activating the cGAS-STING signaling pathway in diabetic nephropathy (DN). Inhibiting PCSK9 with mAbs or siRNA effectively reduces inflammation and delays the progression of DN. Furthermore, the inhibition of STING significantly blocks the inflammation triggered by HGPA in HK-2 cells.
Letter
Cardiac & Cardiovascular Systems
Fotios Barkas, Moses Elisaf, Evangelos C. Rizos, Evangelos Liberopoulos
Review
Cardiac & Cardiovascular Systems
Eleni Pappa, Christos V. Rizos, Theodosios D. Filippatos, Moses S. Elisaf
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
(2019)
Article
Medicine, General & Internal
Kostas Archontogeorgis, Nikolaos Papanas, Evangelos C. Rizos, Evangelia Nena, Athanasios Zissimopoulos, Christina Tsigalou, Athanasios Voulgaris, Dimitri P. Mikhailidis, Moses S. Elisaf, Marios E. Froudarakis, Paschalis Steiropoulos
MEDICINA-LITHUANIA
(2019)
Article
Endocrinology & Metabolism
Ioannis Akoumianakis, Theodosios Filippatos
Review
Gastroenterology & Hepatology
T. D. Filippatos, K. Alexakis, V Mavrikaki, D. P. Mikhailidis
Summary: NAFPD is associated with obesity, MetS, T2DM, and atherosclerosis. Various detection methods, including endoscopic ultrasonography, play a role in understanding NAFPD. The accumulation of fat in pancreatic tissue may impact beta-cell function, carbohydrate metabolism, and atherosclerosis.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Review
Peripheral Vascular Disease
Ioannis Akoumianakis, Evangelia Zvintzou, Kyriakos Kypreos, Theodosios D. Filippatos
Summary: Recent studies have identified ANGPTL3 and Apo C-III as novel regulators of triglyceride and low-density lipoprotein-cholesterol levels, with potential for significant reductions in LDL-C and TG levels in clinical trials. Further research is needed to evaluate the safety and efficacy of targeting these molecules for lipid-lowering strategies.
CURRENT ATHEROSCLEROSIS REPORTS
(2021)
Review
Neurosciences
Fotios Barkas, Sebastian Filippas Ntekouan, Evangelos Liberopoulos, Theodosios Filippatos, Haralampos Milionis
Summary: SGLT2i treatment can reduce the risk of stroke in patients with type 2 diabetes and impaired renal function, with a significant protective effect against hemorrhagic stroke.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
(2021)
Article
Medicine, General & Internal
Petros Ioannou, Symeon Panagiotakis, Emmanouela Tsagkaraki, Constantinos Tsioutis, Konstantinos Fragkiadakis, Achilleas Gikas, Theodosios D. Filippatos
Summary: Hyponatremia is a common electrolyte disorder that often affects older hospitalized individuals and can have an impact on mortality. The main cause is hypovolemia, with a significant proportion of patients not meeting the criteria for SIAD at admission. Re-admission rates and mortality are higher in patients with hyponatremia at admission.
JOURNAL OF CLINICAL MEDICINE
(2021)
Editorial Material
Peripheral Vascular Disease
Theodosios D. Filippatos
Article
Cardiac & Cardiovascular Systems
Filippos Anastasiadis, Dimitrios Antoniadis, Dimitrios Chountis, Ioannis Mantas, Ioannis Lekakis, Moses Elisaf, Charalampos Karvounis, Athanasios Manolis, Georgios Hahalis, Ioannis Kogias, Theodora Tourtoglou, Dimitrios Gourlis, Dimitrios Tsounis
Summary: Based on the TIGREECE study in Greece, the long-term outcomes of high-risk myocardial infarction patients managed in hospitals and private clinics show that approximately 10% of patients experience recurrent cardiovascular events or death within 1-3 years, mainly of ischemic origin.
HELLENIC JOURNAL OF CARDIOLOGY
(2023)
Article
Nutrition & Dietetics
Eleni A. Karavia, Panagiota C. Giannopoulou, Vassiliki Konstantinopoulou, Katerina Athanasopoulou, Theodosios D. Filippatos, Demosthenes Panagiotakos, Kyriakos E. Kypreos
Summary: We used the GRADE tool to evaluate the quality of evidence from phase III/IV clinical trials of drugs against obesity. Our systematic review assessed the quality of clinical evidence from existing trials, rather than the pharmacological efficacy of anti-obesity therapies. We found that the overall quality of clinical evidence from anti-obesity trials ranged from low to moderate, with most trials affected by publication bias, and some trials having a risk of bias due to lack of blinding in treatment.
Review
Endocrinology & Metabolism
Ioannis Akoumianakis, Anastasios Zagaliotis, Maria Konstantaraki, Theodosios D. Filippatos
Summary: GLP-1 analogs have been found to reduce the deposition of abdominal fat, subcutaneous fat, total fat, epicardial fat, and liver fat, and may have significant roles in combating metabolic, obesity-associated diseases.
Article
Virology
Petros Ioannou, Athanasios Katsigiannis, Ioanna Papakitsou, Ioannis Kopidakis, Eirini Makraki, Dimitris Milonas, Theodosios D. Filippatos, George Sourvinos, Marina Papadogiannaki, Evaggelia Lydaki, Georgios Chamilos, Diamantis P. Kofteridis
Summary: Patients receiving B-cell-depleting monoclonal antibodies have an increased risk for medical complications and mortality from COVID-19. The use of convalescent plasma (CP) in these patients is unclear and further studies are needed. This study aims to describe patient characteristics and the potential benefits of CP in terms of mortality, ICU admission, and disease relapse. Results showed that patients treated with CP had a lower re-admission rate for COVID-19, suggesting a potential positive effect.
Article
Infectious Diseases
Petros Ioannou, Despoina Spentzouri, Myrto Konidaki, Michalis Papapanagiotou, Sotiris Tzalis, Ioannis Akoumianakis, Theodosios D. Filippatos, Symeon Panagiotakis, Diamantis P. Kofteridis
Summary: This study investigated the clinical characteristics of hospitalized older patients with COVID-19 and described their outcomes. The study found that older age and the need for HFNO were associated with higher mortality risk.
INFECTIOUS DISEASE REPORTS
(2022)
Review
Pharmacology & Pharmacy
Ioanna Papakitsou, George Vougiouklakis, Moses S. Elisaf, Theodosios D. Filippatos
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS
(2019)
